2. UroToday Home
  3. Center Of Excellence

Centers of Excellence

Radioligand Therapy in Prostate Cancer

Curated by clinicians: educational forums with videos, abstracts and conference information
Dr. Charles J. Ryan, MD

A. Oliver Sartor, MD,

Director of the Transformational Prostate Cancer Research Center at Tulane University School of Medicine.

He is a recognized leader in prostate cancer research and radioligand therapy, with expertise spanning clinical investigation, treatment development, and multidisciplinary care. View Full Bio

This Center examines the evolving role of radioligand therapy across prostate cancer disease states, providing expert perspectives on emerging evidence, patient selection, treatment sequencing, safety, and real-world implementation.

RLT in Metastatic Hormone-Sensitive Prostate Cancer

RLT in Pre-Chemotherapy mCRPC

RLT in Post-Chemotherapy mCRPC

RLT Implementation and Multidisciplinary Care

Phase 2 TheraPb Trial Evaluates a Novel Induction and Maintenance Regimen of 212Pb-ADVC001 Across Three Metastatic Prostate Cancer Indications - Anna Karmann
Integrating Lutetium-177-PSMA-617: Sequencing, Combinations, and Safety in Taxane-Naïve mCRPC - Michael Morris
Implementing Radioligand Therapy in a Urology Practice: A Discussion of Practical, Regulatory, and Team Considerations - Neal Shore
Implementing Lutetium-PSMA — From Trial Design to Operations - Oliver Sartor
Integrating PSMA PET Imaging: From Interpretation to Systemic Therapy Selection in Castration-Resistant Prostate Cancer - Oliver Sartor
Lutetium-177 PSMA Radioligand Therapy Advances to Earlier mCRPC Setting - Daniel Petrylak & Steven Finkelstein
Health-Related Quality Outcomes for Pre-Chemotherapy mCRPC Treatment - Neal Shore
First Patient Experience with Pre-Chemotherapy Pluvicto™ for mCRPC Treatment - James Wasielewski
First Patient Treated with Pluvicto™ in Pre-Chemotherapy Setting Following FDA Approval - Steven Finkelstein
Integration of Lutetium-177 and the Value of Shared Decisions with Practice Stakeholders - Jeffrey Zemencik
Expanding the Nuclear Hot Lab to Accommodate Lutetium-177 - Lyanne Gomez
Finding the Right Patient for Lutetium-177 PSMA Treatment - Kara Cossis
Coordinating & Transitioning Patient Care for Patients Who Receive Lutetium-177 - Elizabeth Davis
A Urologist’s Multidisciplinary Approach to Clinical Management of the Patient Receiving Lutetium-177 - Benjamin Lowentritt
Radiation Safety Considerations for the Authorized User when Operationalizing Lutetium-177 in the Urology Clinic - Robert Brookland
Multidisciplinary Transitions in Care for Patients Receiving Lutetium-177 - Benjamin Lowentritt & Robert Brookland
Operationalizing Lutetium-177-PSMA Programs - William Oresick
How One Urology Clinic Successfully Sets Up a Hot Lab for Radioligand Therapy Program - William Oresick
Clinical Considerations for Patient Selection for Lutetium-177 PSMA- Gordon Brown
Patient Navigation in the Advanced Prostate Clinic for Lutetium-177 PSMA Therapy - Christina Fareri
Lutetium-177 PSMA in Urology: Radiation Safety and Authorized User Considerations - Glen Gejerman
Summit Health's Approach to Incorporating Lutetium-177 PSMA in the Multidisciplinary Setting - Gordon Brown & Glen Gejerman
Real-world Experiences Associated with Treating Patients With Lutetium-177 PSMA in a High-volume Care Center - Thomas Hope
Lutetium-617 - Treatment Sequencing Considerations for Metastatic Castration-Resistant Prostate Cancer - Neal Shore
Imaging and PET Analysis as a Prognostic Tool for Lu-PSMA-617 Treatment in Patients with mCRPC - Phillip H. Kuo
Integrating 177Lu-PSMA-617 in Clinical Practice - Oliver Sartor
Methods for Preparation and Administration of Pluvicto™ (177Lu-PSMA-617) - Kendra Harris
Preparing for Treatment with 177Lu-PSMA-617 - Kendra Harris
Administering Pluvicto™ - A Patient Shares His Treatment Experience of 177Lu-PSMA-617 - Kendra Harris and Phillip Koo
Integration of Pluvicto™ (177Lu-PSMA-617) in Clinical Practice - Oliver Sartor and Kendra Harris
Radiation Safety and the Integration of Pluvicto™ (177Lu-PSMA-617) in Treatment of mCRPC- Kendra Harris
Building a Sustainable Radioligand Treatment Clinic – Charlotte Manogue
Patient Management and Operationalizing Lutetium-177–PSMA-617 for Metastatic Castration Resistant Prostate Cancer in the Clinic – Charlotte Manogue and Oliver Sartor
Establishing A Theranostics Clinic for Advanced Prostate Cancer – Kendra Harris and Charlotte Manogue
The Stakeholders in Operationalizing an Integrated PSMA Imaging and Therapies Clinic - Kendra Harris
Conference Coverage
Conference Highlights Written by Physician Scientists
Presented by Louise Emmett, MD, MBChB, FRACP, FAANMS
(UroToday.com) The 2026 ASCO annual meeting featured an optimizing care for patients with metastatic castration resistant prostate cancer (mCRPC) session and a presentation by Dr. Louise Emmett discussing how to better personalize treatment with 177Lu-PSMA-617. How stringent should patient selection criteria be?
Presented by Fred Saad, CQ, MD, FRCS, FCAHS
Fred Saad, CQ, MD, FRCS, FCAHS, presented the results of subgroup analyses by disease volume and timing (de novo versus recurrent) from the PSMAddition study of [177Lu]Lu-PSMA-617] in the metastatic hormone-sensitive prostate cancer (mHSPC) setting.